Pharmafile Logo
Pharmafocus logo
Advanced Search

Roche

Showing 15 posts of 710 posts found.

Roche to challenge FDA on Avastin

December 21, 2010
Sales and Marketing EMA, FDA, Roche, avastin, bevacizumab, breast cancer

Roche is set to challenge the decision by the FDA to remove a breast cancer indication from its blockbuster drug …

News

Boehringer puts afatinib head-to-head with Herceptin

December 10, 2010
Research and Development BIBW 2992, Boehringer Ingelheim, Herceptin, Roche, Tovok, afatinib, breast cancer

Boehringer Ingelheim has set up a showdown between one of its pipeline oncology products and Roche’s Herceptin. It has started …

News

Roche highlights R&D promise after setbacks

December 9, 2010
Research and Development MS, Roche, oncology, personalised medicine, schizophrenia

Roche has presented its pipeline to shareholders to boost confidence that it can sustain the spectacular growth of recent years. …

News
Avastin packs

NICE no for Avastin in breast cancer

December 8, 2010
Sales and Marketing NICE, Roche, avastin, bevacizumab, breast cancer, health technology assessment, hta

NICE has refused to back Roche’s Avastin for use in breast cancer patients citing the blockbuster drug’s high cost and …

News

Roche’s MabThera successor shows phase II promise

December 6, 2010
Research and Development, Sales and Marketing GA101, Genentech, GlycArt, MabThera, Roche, blood cancer, chronic lymphocytic leukaemia

The cancer drug Roche is developing as a second-generation successor to its blockbuster MabThera has shown promising results in a …

News
Roche's MabThera

NICE recommends MabThera for non-Hodgkin’s lymphoma

December 6, 2010
Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab

NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …

News
Tarceva tablet

Roche set to challenge NICE Tarceva decision

November 25, 2010
Sales and Marketing NICE, Roche, Roche UK, Tarceva, erlotinib, lung cancer

NICE has again rejected Roche’s lung cancer drug Tarceva in its second round of draft guidance. Tarceva (erlotinib) was being …

News

Pharma manufacturing news in brief

November 23, 2010
Manufacturing and Production Alpah Biologics, Alpha Biologics, Kemwell, Lonza, Phil Taylor, Roche

Facility updates from Roche, Alpha Biologics, Kemwell and Reinnervate, new contract services from Lonza and Patheon, plus a milestone in …

News

Roche to develop diagnostic tools for Tarceva

November 23, 2010
Sales and Marketing Genzyme, NSCLC, Roche, Tarceva, diagnostic

Roche has obtained a worldwide sub-license from Genzyme to develop a diagnostic kit for the detection of specific mutations for …

News
Age-related macular degeneration (Wet AMD)

Bayer’s challenger to Lucentis shows promise

November 22, 2010
Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD

Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …

News
Roche job cuts

Roche set to cut 4,800 jobs worldwide

November 17, 2010
Manufacturing and Production, Research and Development, Sales and Marketing Jobs, Roche, avastin, cuts, taspoglutide

Roche’s ‘Operational Excellence’ programme will see it cut 6% of its global workforce over the next two years. The initiative …

News
Big Blue Test

Digital Pharma: Diabetes video goes viral

November 16, 2010
Medical Communications, Sales and Marketing Diabetes Hands Foundation, Digital Pharma blog, Roche, diabetes, viral video, youtube

An online video encouraging diabetics to test their blood sugar levels has passed 117,000 views on YouTube in just over …

News
Avastin packs

NICE stands firm on Avastin rejection

November 12, 2010
Sales and Marketing NICE, Roche, avastin, bevacizumab, colon cancer, metastatic colorectal cancer, patient access scheme

NICE has refused to recommend Roche’s blockbuster cancer drug Avastin for the treatment of metastatic colorectal cancer in its final …

News

Roche’s melanoma candidate impresses in phase II trials

November 5, 2010
Research and Development BRAF protein, Cancer, Phase II, Plexxikon, RG7204, Roche

Roche’s mid-stage melanoma candidate has produced positive results in a difficult to treat cancer. RG7204 is an investigational, first-in-class molecule …

News

MabThera gains maintenance therapy licence

October 29, 2010
Medical Communications, Sales and Marketing MabThera, Rituxan, Roche, lymphoma

Roche’s MabThera has been approved as a maintenance therapy for follicular lymphoma, a common type of blood cancer. Maintenance treatment …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026